Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

Bruce L. Levine, Marcelo C. Pasquini, John E. Connolly, David L. Porter, Michael P. Gustafson, Jaap J. Boelens, Edwin M. Horwitz, Stephan A. Grupp, Marcela V. Maus, Frederick L. Locke, Fabio Ciceri, Annalisa Ruggeri, John Snowden, Helen E. Heslop, Crystal L. Mackall, Carl H. June, Anna M. Sureda, Miguel Angel Perales

Research output: Contribution to journalComment/debatepeer-review

24 Scopus citations

Abstract

Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.

Original languageEnglish (US)
Pages (from-to)338-341
Number of pages4
JournalNature Medicine
Volume30
Issue number2
DOIs
StatePublished - Feb 2024

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Unanswered questions following reports of secondary malignancies after CAR-T cell therapy'. Together they form a unique fingerprint.

Cite this